Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.02M P/E - EPS this Y - Ern Qtrly Grth -
Income -21.86M Forward P/E - EPS next Y - 50D Avg Chg -41.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -95.00%
Dividend N/A Price/Book 0.02 EPS next 5Y - 52W High Chg -99.00%
Recommedations 2.00 Quick Ratio 0.01 Shares Outstanding 1.07M 52W Low Chg 6.00%
Insider Own 0.61% ROA -24.92% Shares Float 1.02M Beta 0.64
Inst Own 5.18% ROE -152.23% Shares Shorted/Prior 17.88K/40.87K Price 0.17
Gross Margin - Profit Margin - Avg. Volume 2,226,495 Target Price 70.00
Oper. Margin - Earnings Date Aug 9 Volume 908,446 Change -0.18%
About ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

ZyVersa Therapeutics, Inc. News
12/18/24 ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
11/21/24 OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR
11/20/24 ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
11/15/24 Life Sciences Investor Forum: Presentations Now Available for Online Viewing
11/14/24 ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
11/12/24 Life Sciences Investor Forum Agenda Announced for November 14th
11/05/24 ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
10/29/24 ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
10/22/24 ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
10/17/24 ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
10/15/24 ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
10/07/24 ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
08/09/24 ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
08/07/24 ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
07/29/24 ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
07/25/24 ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
07/18/24 ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
07/09/24 ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
05/15/24 ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
05/14/24 ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention